FDA to Boost Post Marketing Safety Activities
Posted on: Friday, 9 May 2008, 09:01 CDT
The FDA has reported that it will expand its post marketing safety activities, and adopt new scientific approaches to drug safety to meet its commitments under the Prescription Drug User Fee Act.
The agency plans to spend its Prescription Drug User Fee Act (PDUFA IV) fees to fund epidemiology best practices and data acquisition. According to the Drug Safety Five-Year Plan draft, the FDA intends to use the fees to increase the number of employees dedicated to adopting new scientific approaches to drug safety, reducing the risk of medication errors and improving adverse event detection and prevention programs.
In another use of the new PDUFA funds, the FDA plans to develop and implement agency wide and special-purpose postmarket IT systems, including the MedWatch Plus Portal, the FDA Adverse Event Reporting System, the Sentinel System (a virtual national medical product safety system) and the Phonetic and Orthographic Computer Analysis System to find similarities in spelling or sound between proposed proprietary drug names that might increase the risk of confusion and medication errors.
The FDA also plans to hire a contractor to study the various mechanisms for collecting adverse events and determine optimal strategies for collecting adverse event data throughout the product lifecycle.
Source: Datamonitor
Related Articles
- SRA Selects Oracle(R) Adverse Event Reporting System
- FDA Posts Drug-Safety Watch List
- WellPoint Announces Development of Innovative Drug Safety System Designed to Monitor Drug and Therapy Risks Post-FDA Approval
- Commenting on the U.S. Food and Drug Administration (FDA) Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX(R), Rather Than BOTOX(R) Cosmetic for Aesthetic Use
- Drug Safety Reform and Risk Management Plans - A Test Case?
- Revamping the U.S. Drug Safety System: Cleveland Clinic's Steven Nissen, MD, Among Featured Participants at Windhover's FDA/CMS Summit
- Senators plan bill to revamp FDA drug safety
- University Professor Proposes Changes to US Drug Safety System
- FDA Raps Biogen's Plan to Track MS Drug's Safety
- Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events
 |
 |
User Comments (0)
RSS Feeds